A Novel Approach of Targeted Immunotherapy against Adenocarcinoma Cells with Nanoparticles Modified by CD16 and MUC1 Aptamers

Figure 2

Evaluation of the binding affinity and specificity of the aptamers. FAM-labeled aptamers were incubated with cells and analyzed by flow cytometry (red lines). FAM-labeled random DNA (lib) was also incubated with the cells and served as the control (black lines). (a and b) Binding of MUC1 aptamer with the MUC1-positive A549 lung cancer cells and the MUC1-negative MDA-MB-231 cells, respectively. (c) Binding of the control HER2 aptamer with A549 cells. (d) Binding of the CD16 aptamer with PBMC.

(a)

(b)

(c)

(d)